Company: XAIR
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023243
Chunk: 83

Company: Beyond Air, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part II, Item 8
Chunk 83
---
6 million, which is expected to be expensed over the weighted average remaining service period of 1.3 years.

The
Company’s 2023 NeuroNos Ltd. Equity Incentive Plan (the “2023 NNOS Plan”) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of NeuroNos Ltd.’s common stock. The
vesting terms of the options issued under the 2025 NNOS Plan are generally four years and they expire ten years from the grant date.
On April 16, 2025, the Company’s Board of Directors approved to reserve for issuance 1,525,000 shares of common stock. As of June
30, 2025, 146,296 shares were available under the 2023 NNOS Plan.

A
summary of the change in stock options for NeuroNos for the three months ended June 30, 2025 is as follows:

 SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS 

    Number of Options  
    Weighted Average Exercise Price of Options  
    Weighted Average Remaining Contractual Life of Options  
    Aggregate Intrinsic Value (thousands) 

    Options outstanding as of March 31, 2025 
     1,224,139  
    $0.14  
     9.0  
    $3,501 
  
    Granted 
     156,000  
     3.00  
     -  
     - 
  
    Exercised 
     -  
     -  
     -  
     - 
  
    Forfeited 
     (1,435) 
     0.14  
     -  
     - 
  
    Outstanding as of June 30, 2025 
     1,378,704  
    $0.46  
     8.5  
    $3,497 
  
    Exercisable as of June 30, 2025 
     306,035  
    $0.14  
     8.8  
    $875 

As
of June 30, 2025, the Company had unrecognized stock-based compensation expense for the stock options in the 2023 NNOS Plan of approximately
$0.4 million, which is expected to be expensed over the weighted average remaining service period of